Private Placement OncoImmunity AS
Share the transaction
July 2018 – Private Placement OncoImmunity AS
About the deal
In 2018 Bryan, Garnier & Co acted as sole manager for the NOK 60 million Share Placement in OncoImmunity.
The proceeds will be used to further commercialize OncoImmunity’s neoantigen prediction SaaS software and will allow the company to scale up its sales and R&D organization.
Deal team
Erik Furnes | Managing Director | Oslo | Investment Banking | efurnes@bryangarnier.com
Rolf Henning Lem | Director | Oslo | Investment Banking | rlem@bryangarnier.com
About OncoImmunity
OncoImmunity is a machine-learning company offering proprietary technology to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity’s software facilitates effective patient selection for cancer immunotherapy, and identifies optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in a clinically actionable time-frame.